EP 4110823 A1 20230104 - POLYPEPTIDES TARGETING MAGE-A3 PEPTIDE-MHC COMPLEXES AND METHODS OF USE THEREOF
Title (en)
POLYPEPTIDES TARGETING MAGE-A3 PEPTIDE-MHC COMPLEXES AND METHODS OF USE THEREOF
Title (de)
GEGEN MAGE-A3-PEPTID-MHC-KOMPLEXE GERICHTETE POLYPEPTIDE UND VERFAHREN ZU DEREN VERWENDUNG
Title (fr)
POLYPEPTIDES CIBLANT DES COMPLEXES MAGE-A3 PEPTIDE-MHC ET LEURS MÉTHODES D'UTILISATION
Publication
Application
Priority
- US 202062981940 P 20200226
- US 202063076123 P 20200909
- US 2021019420 W 20210224
Abstract (en)
[origin: WO2021173674A1] The present disclosure relates to antibodies and antigen-binding fragments thereof that bind to a MAGE-A3 peptide-MHC complex (pMHC) thereof. Also provided are chimeric antigen receptors and host cells comprising them. The compositions of the disclosure are useful in the diagnosis and treatment of cancer, including hematological malignancies, solid tumors, and epithelial cancers. In particular, provided are polypeptides that specifically bind to a pMHC complex displaying a MAGE-A3 peptide over a EPS8L2 pMHC complex displaying the EPS8L2 peptide SAAELVHFL (SEQ ID NO: 333), and methods of use thereof in treating cancer.
IPC 8 full level
C07K 16/30 (2006.01); A61K 39/00 (2006.01); C07K 14/725 (2006.01)
CPC (source: EP)
A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/4632 (2023.05); A61K 39/464486 (2023.05); C07K 14/4748 (2013.01); C07K 14/7051 (2013.01); C07K 16/30 (2013.01); C07K 2317/21 (2013.01); C07K 2317/32 (2013.01); C07K 2317/565 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
DOCDB simple family (application)
US 2021019420 W 20210224; EP 21713215 A 20210224